US biopharmaceutical company Sterotherapeutics announced on Monday that it has launched a Phase 2 clinical trial of ST-002, a novel drug candidate for patients with Cushing's Syndrome, a rare endocrine disorder with very limited available therapeutic options.
An Investigators Meeting to start the study has taken place in Athens, Greece, when clinical investigators, research coordinators and stakeholders discussed trial objectives, protocol details and best practices.
The Phase 2 trial is intended to assess the safety, efficacy and tolerability of ST-002 in patients with Cushing's syndrome.
Caused by prolonged exposure to excessive cortisol levels, Cushing's syndrome can lead to severe complications such as diabetes, hypertension, osteoporosis and increased mortality if left untreated.
Sterotherapeutics has received orphan drug designation for ST-002 from the US Food and Drug Administration (FDA).
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval